New algorithms based on factors identifying the liver disease status (e.g., albumin, alpha-fetoprotein, liver stiffness measurement) and risk of progression (e.g., alcohol consumption) and age (a strong driver of carcinogenesis) have been developed to stratify patients according to the risk of liver cancer development [34] in order to avoid non-cost-effective surveillance. This evidence concerns the gene AFP and liver cancer.